Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:United_States_federal_law
|
| gptkbp:administeredBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:appliesTo |
clinical investigators
drug manufacturers |
| gptkbp:codifiedIn |
gptkb:Title_21_of_the_United_States_Code
|
| gptkbp:dateEnacted |
1962
|
| https://www.w3.org/2000/01/rdf-schema#label |
21 U.S.C. 355(i)
|
| gptkbp:jurisdiction |
gptkb:United_States
|
| gptkbp:partOf |
gptkb:Federal_Food,_Drug,_and_Cosmetic_Act
gptkb:21_U.S.C._355 |
| gptkbp:regulates |
clinical investigations of drugs
|
| gptkbp:requires |
submission of investigational new drug application (IND)
|
| gptkbp:subject |
gptkb:Investigational_new_drug_applications
|
| gptkbp:bfsParent |
gptkb:21_CFR_56
|
| gptkbp:bfsLayer |
6
|